Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia.
Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia.
复制标题
卡马西平-伊马替尼在慢性粒细胞白血病儿童中的相互作用。
DOI：
10.1111/ped.12382
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Saito H.
中科院分区：
文献类型：
--
作者：
Taguchi K;Kouroki M;Ohmura T;Jono H;Endo F;Saito H.
甲磺酸伊马替尼是一种选择性酪氨酸激酶抑制剂，是治疗慢性粒细胞白血病(CML)的一线药物，其疗效与药物浓度有关。因此，为了成功治疗CML患者，强烈建议监测伊马替尼谷浓度。最近有研究表明，一些药物会改变成年患者的伊马替尼血药浓度。然而，药物与伊马替尼在儿童中的相互作用仍不清楚。在这里，我们报告了一例12岁的癫痫儿童，他也被诊断为慢性粒细胞白血病，在服用酶诱导的抗癫痫药物卡马西平的同时服用伊马替尼。与群体动力学数据相比，患者的数据显示伊马替尼的血药浓度显著降低。我们的研究结果表明，需要监测接受酶诱导抗癫痫药物治疗的儿童的伊马替尼血药浓度，以优化伊马替尼的治疗效果。
Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12‐year‐old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme‐inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme‐inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.